Semaglutide vs Older Diabetes Drugs

Type 2 diabetes has more treatment options than most people realize, and the older ones are still what most patients start on. Sulfonylureas, DPP-4 inhibitors and thiazolidinediones have been standard oral therapy for decades. Semaglutide, the GLP-1 receptor agonist sold as Ozempic and Rybelsus, is newer and works differently. Head-to-head trial data comparing the two approaches is more limited than people assume, but where it exists, the pattern is consistent^[1].

The strongest comparison: semaglutide versus DPP-4 inhibitors

The clearest trial evidence sits here, because DPP-4 inhibitors (sitagliptin is the most-studied) have been used as the active comparator in several semaglutide trials rather than just as background therapy. In PIONEER 3, a 78-week randomized trial published in JAMA, 1,864 adults with type 2 diabetes on metformin (with or without a sulfonylurea) were assigned to oral semaglutide or sitagliptin. At 26 weeks, the 14 mg semaglutide dose lowered HbA1c by 1.3 percentage points against sitagliptin's 0.8, a difference of 0.5 points that held up statistically (95% CI, -0.6 to -0.4; P<.001). Body weight fell 3.1 kg on semaglutide 14 mg versus 0.6 kg on sitagliptin

The injectable version tells the same story. A 2023 meta-analysis in Annals of Medicine pooled three SUSTAIN-programme trials (2,401 participants total) comparing once-weekly semaglutide against sitagliptin as an add-on to metformin. Semaglutide produced an HbA1c reduction 0.98 percentage points larger than sitagliptin and 3.17 kg more weight loss, both statistically significant. Adverse events were slightly more common with semaglutide overall, driven mostly by gastrointestinal side effects, and more patients stopped semaglutide early because of them

The European Medicines Agency's assessment of Ozempic reports the same direction. It lists HbA1c reductions of 1.2 to 1.8 percentage points against comparator drugs, including a 0.55-point reduction on sitagliptin recorded over the same trial period^[3]. A phase 3a RCT, a pooled meta-analysis, and a regulator's own review of the trial data all point the same way. On HbA1c and body weight, semaglutide outperforms sitagliptin by a margin wide enough that none of the three needed a large sample to detect it.

Sulfonylureas and thiazolidinediones: a thinner trial record

Sulfonylureas (glimepiride, glipizide, glyburide) and thiazolidinediones such as pioglitazone are older still. Sulfonylureas were introduced in the 1950s and work by forcing the pancreas to release insulin regardless of the current blood glucose level, which is why they carry a real hypoglycemia risk and tend to cause weight gain over time. Thiazolidinediones improve how sensitive fat and muscle tissue are to the insulin the body already makes, but they come with fluid retention, weight gain, and a bone-fracture signal in postmenopausal women that has limited their use since the mid-2000s.

Neither class has been tested against semaglutide in a dedicated head-to-head randomized trial the way sitagliptin has. Both classes do turn up as background therapy inside semaglutide's own trial programme. SUSTAIN 2 allowed patients who were already on metformin plus a thiazolidinedione. PIONEER 3 allowed a background sulfonylurea alongside metformin. That tells us semaglutide is safe to add on top of those drugs, but it is not the same as a trial designed to compare the two head to head.

That gap is worth naming plainly rather than glossing over. The confident, trial-backed claim here is about semaglutide versus DPP-4 inhibitors specifically. Extending it to sulfonylureas or thiazolidinediones would go beyond what the randomized trials actually tested, even though the drug mechanisms make a similar pattern plausible.

What the FDA label adds

Beyond glycemic control, Ozempic's current FDA prescribing information lists indications that sulfonylureas, DPP-4 inhibitors and thiazolidinediones don't carry: reducing major cardiovascular events in patients with type 2 diabetes and established cardiovascular disease, and reducing the risk of kidney function decline and cardiovascular death in patients with type 2 diabetes and chronic kidney disease^[4]. The label also carries a boxed warning about thyroid C-cell tumors seen in rodent studies, with unknown relevance to humans, and a contraindication for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.

None of the three older classes has cardiovascular or kidney outcome data of that kind on its label. That doesn't make them the wrong choice for a given patient. Sulfonylureas are inexpensive and familiar, and that matters in health systems or insurance plans where cost limits what a patient can actually access. The narrower point stands on its own: the outcome evidence behind semaglutide currently reaches further than glycemic control alone, and that is a genuine difference in what the trial and label evidence supports, separate from how each drug performs on HbA1c.

What this means for readers

None of this is a recommendation to switch medications. Trial averages describe groups, not individuals, and a drug that outperforms another on paper isn't automatically the right fit for someone with a specific history of side effects, cost constraints, or comorbidities. The literature reports that semaglutide outperforms sitagliptin on HbA1c and weight in controlled trials, and that its cardiovascular and kidney indications go further than older oral drugs currently carry. What it costs, what it's covered for, and whether it's appropriate for a given patient is a conversation for a prescribing clinician, not a question these trial numbers can settle on their own. See the semaglutide regulation pages for how each formulation is approved and dispensed by country.